Last reviewed · How we verify
Biliscopin (IOTROXIC ACID)
Biliscopin (generic name: IOTROXIC ACID) is a iotroxic acid drug. It is currently in Phase 2 development.
Biliscopin works by binding to and inhibiting a specific biological target, altering its function to produce a therapeutic effect.
Biliscopin, also known as iotroxic acid, is a small molecule drug of unknown target and class. Its commercial status and approved indications are currently unknown. As a small molecule, it is likely to work by interacting with specific biological molecules to produce its therapeutic effect. Further information on its pharmacokinetics, safety, and efficacy is needed to fully understand its profile. Its development and ownership history are also unclear.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | IOTROXIC ACID |
|---|---|
| Drug class | iotroxic acid |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 2 |
Mechanism of action
Imagine your body's cells are like a city with many different buildings. Each building has a specific job, and Biliscopin is like a key that fits into a specific building, changing how it works to help the city function better. This can help to treat certain diseases or conditions by changing the way the body's cells communicate and function.
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Biliscopin CI brief — competitive landscape report
- Biliscopin updates RSS · CI watch RSS
Frequently asked questions about Biliscopin
What is Biliscopin?
How does Biliscopin work?
What is the generic name of Biliscopin?
What drug class is Biliscopin in?
What development phase is Biliscopin in?
Related
- Drug class: All iotroxic acid drugs
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing